ID   TRPV1_RAT               Reviewed;         838 AA.
AC   O35433; Q920B3; Q920B4; Q9JLM0; Q9JM56; Q9JM57;
DT   10-MAY-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   02-OCT-2024, entry version 195.
DE   RecName: Full=Transient receptor potential cation channel subfamily V member 1;
DE            Short=TrpV1;
DE   AltName: Full=Capsaicin receptor;
DE   AltName: Full=Osm-9-like TRP channel 1;
DE            Short=OTRPC1;
DE   AltName: Full=Vanilloid receptor 1;
DE   AltName: Full=Vanilloid receptor type 1-like;
GN   Name=Trpv1; Synonyms=Vr1, Vr1l;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION,
RP   TISSUE SPECIFICITY, AND TRANSPORTER ACTIVITY.
RC   TISSUE=Spinal ganglion;
RX   PubMed=9349813; DOI=10.1038/39807;
RA   Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D.,
RA   Julius D.;
RT   "The capsaicin receptor: a heat-activated ion channel in the pain
RT   pathway.";
RL   Nature 389:816-824(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), TISSUE SPECIFICITY, AND FUNCTION
RP   (ISOFORM 3).
RC   STRAIN=Sprague-Dawley; TISSUE=Spinal ganglion, and Trigeminal ganglion;
RX   PubMed=10644739; DOI=10.1074/jbc.275.4.2756;
RA   Schumacher M.A., Moff I., Sudanagunta S.P., Levine J.D.;
RT   "Molecular cloning of an N-terminal splice variant of the capsaicin
RT   receptor. Loss of N-terminal domain suggests functional divergence among
RT   capsaicin receptor subtypes.";
RL   J. Biol. Chem. 275:2756-2762(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, SUBCELLULAR
RP   LOCATION, AND TRANSPORTER ACTIVITY.
RX   PubMed=11578842; DOI=10.1016/s0304-3940(01)02185-1;
RA   Tsutsumi S., Tomioka A., Sudo M., Nakamura A., Shirakura K., Takagishi K.,
RA   Kohama K.;
RT   "Propofol activates vanilloid receptor channels expressed in human
RT   embryonic kidney 293 cells.";
RL   Neurosci. Lett. 312:45-49(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-468, AND ALTERNATIVE SPLICING.
RC   STRAIN=Sprague-Dawley;
RX   PubMed=11549313; DOI=10.1006/geno.2001.6582;
RA   Xue Q., Yu Y., Trilk S.L., Jong B.E., Schumacher M.A.;
RT   "The genomic organization of the gene encoding the vanilloid receptor:
RT   evidence for multiple splice variants.";
RL   Genomics 76:14-20(2001).
RN   [5]
RP   CHARACTERIZATION OF CHANNEL PORE, AND MUTAGENESIS OF GLU-636; LYS-639;
RP   MET-644; ASP-646; GLU-648 AND GLU-651.
RX   PubMed=10931826; DOI=10.1074/jbc.m002391200;
RA   Garcia-Martinez C., Morenilla-Palao C., Planells-Cases R., Merino J.M.,
RA   Ferrer-Montiel A.V.;
RT   "Identification of an aspartic residue in the P-loop of the vanilloid
RT   receptor that modulates pore properties.";
RL   J. Biol. Chem. 275:32552-32558(2000).
RN   [6]
RP   FUNCTION, AND TRANSPORTER ACTIVITY.
RX   PubMed=11140687; DOI=10.1038/35050121;
RA   Premkumar L.S., Ahern G.P.;
RT   "Induction of vanilloid receptor channel activity by protein kinase C.";
RL   Nature 408:985-990(2000).
RN   [7]
RP   SUBCELLULAR LOCATION, AND GLYCOSYLATION AT ASN-604.
RX   PubMed=11683872; DOI=10.1046/j.1432-1033.2001.02500.x;
RA   Jahnel R., Dreger M., Gillen C., Bender O., Kurreck J., Hucho F.;
RT   "Biochemical characterization of the vanilloid receptor 1 expressed in a
RT   dorsal root ganglia derived cell line.";
RL   Eur. J. Biochem. 268:5489-5496(2001).
RN   [8]
RP   FUNCTION, AND INTERACTION WITH PRKCG AND NTRK1.
RX   PubMed=11418861; DOI=10.1038/35082088;
RA   Chuang H.H., Prescott E.D., Kong H., Shields S., Jordt S.E., Basbaum A.I.,
RA   Chao M.V., Julius D.;
RT   "Bradykinin and nerve growth factor release the capsaicin receptor from
RT   PtdIns(4,5)P2-mediated inhibition.";
RL   Nature 411:957-962(2001).
RN   [9]
RP   PHOSPHORYLATION AT SER-502 AND SER-800, AND MUTAGENESIS OF SER-502 AND
RP   SER-800.
RX   PubMed=11884385; DOI=10.1074/jbc.c200104200;
RA   Numazaki M., Tominaga T., Toyooka H., Tominaga M.;
RT   "Direct phosphorylation of capsaicin receptor VR1 by protein kinase
RT   Cepsilon and identification of two target serine residues.";
RL   J. Biol. Chem. 277:13375-13378(2002).
RN   [10]
RP   FUNCTION, AND TRANSPORTER ACTIVITY.
RX   PubMed=12095983; DOI=10.1074/jbc.m201551200;
RA   Olah Z., Karai L., Iadarola M.J.;
RT   "Protein kinase C(alpha) is required for vanilloid receptor 1 activation.
RT   Evidence for multiple signaling pathways.";
RL   J. Biol. Chem. 277:35752-35759(2002).
RN   [11]
RP   FUNCTION, PHOSPHORYLATION AT SER-116; THR-144; THR-370; SER-502; SER-774
RP   AND SER-820, AND TRANSPORTER ACTIVITY.
RX   PubMed=12194871; DOI=10.1016/s0896-6273(02)00802-4;
RA   Bhave G., Zhu W., Wang H., Brasier D.J., Oxford G.S., Gereau R.W. IV;
RT   "cAMP-dependent protein kinase regulates desensitization of the capsaicin
RT   receptor (VR1) by direct phosphorylation.";
RL   Neuron 35:721-731(2002).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH CALMODULIN.
RX   PubMed=12808128; DOI=10.1073/pnas.1337252100;
RA   Numazaki M., Tominaga T., Takeuchi K., Murayama N., Toyooka H.,
RA   Tominaga M.;
RT   "Structural determinant of TRPV1 desensitization interacts with
RT   calmodulin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:8002-8006(2003).
RN   [13]
RP   FUNCTION, MUTAGENESIS OF SER-502; THR-704 AND SER-800, AND TRANSPORTER
RP   ACTIVITY.
RX   PubMed=14523239; DOI=10.1073/pnas.2032100100;
RA   Bhave G., Hu H.J., Glauner K.S., Zhu W., Wang H., Brasier D.J.,
RA   Oxford G.S., Gereau R.W. IV;
RT   "Protein kinase C phosphorylation sensitizes but does not activate the
RT   capsaicin receptor transient receptor potential vanilloid 1 (TRPV1).";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:12480-12485(2003).
RN   [14]
RP   FUNCTION, MUTAGENESIS OF ARG-785; LYS-788; ARG-797 AND SER-800, AND REGION.
RX   PubMed=12764195; DOI=10.1126/science.1083646;
RA   Prescott E.D., Julius D.;
RT   "A modular PIP2 binding site as a determinant of capsaicin receptor
RT   sensitivity.";
RL   Science 300:1284-1288(2003).
RN   [15]
RP   INTERACTION WITH CSK.
RX   PubMed=15084474; DOI=10.1152/ajpcell.00113.2004;
RA   Jin X., Morsy N., Winston J., Pasricha P.J., Garrett K., Akbarali H.I.;
RT   "Modulation of TRPV1 by nonreceptor tyrosine kinase, c-Src kinase.";
RL   Am. J. Physiol. 287:C558-C563(2004).
RN   [16]
RP   MUTAGENESIS OF ARG-114; ARG-115 AND GLU-761.
RX   PubMed=12228246; DOI=10.1074/jbc.m207103200;
RA   Jung J., Lee S.Y., Hwang S.W., Cho H., Shin J., Kang Y.S., Kim S., Oh U.;
RT   "Agonist recognition sites in the cytosolic tails of vanilloid receptor
RT   1.";
RL   J. Biol. Chem. 277:44448-44454(2002).
RN   [17]
RP   FUNCTION, PHOSPHORYLATION AT SER-502 AND THR-704, AND MUTAGENESIS OF
RP   SER-502 AND THR-704.
RX   PubMed=14630912; DOI=10.1074/jbc.m311448200;
RA   Jung J., Shin J.S., Lee S.-Y., Hwang S.W., Koo J., Cho H., Oh U.;
RT   "Phosphorylation of vanilloid receptor 1 by Ca2+/calmodulin-dependent
RT   kinase II regulates its vanilloid binding.";
RL   J. Biol. Chem. 279:7048-7054(2004).
RN   [18]
RP   MUTAGENESIS OF TYR-511; MET-547 AND THR-550.
RX   PubMed=14996838; DOI=10.1074/jbc.m312577200;
RA   Gavva N.R., Klionsky L., Qu Y., Shi L., Tamir R., Edenson S., Zhang T.J.,
RA   Viswanadhan V.N., Toth A., Pearce L.V., Vanderah T.W., Porreca F.,
RA   Blumberg P.M., Lile J., Sun Y., Wild K., Louis J.C., Treanor J.J.;
RT   "Molecular determinants of vanilloid sensitivity in TRPV1.";
RL   J. Biol. Chem. 279:20283-20295(2004).
RN   [19]
RP   FUNCTION.
RX   PubMed=15173182; DOI=10.1074/jbc.m402966200;
RA   Hellwig N., Plant T.D., Janson W., Schafer M., Schultz G., Schaefer M.;
RT   "TRPV1 acts as proton channel to induce acidification in nociceptive
RT   neurons.";
RL   J. Biol. Chem. 279:34553-34561(2004).
RN   [20]
RP   INTERACTION WITH PRKCM, PHOSPHORYLATION AT SER-116, AND MUTAGENESIS OF
RP   SER-116.
RX   PubMed=15471852; DOI=10.1074/jbc.m410331200;
RA   Wang Y., Kedei N., Wang M., Wang Q.J., Huppler A.R., Toth A., Tran R.,
RA   Blumberg P.M.;
RT   "Interaction between protein kinase Cmu and the vanilloid receptor type
RT   1.";
RL   J. Biol. Chem. 279:53674-53682(2004).
RN   [21]
RP   SUBUNIT, AND DOMAIN.
RX   PubMed=15190102; DOI=10.1523/jneurosci.0202-04.2004;
RA   Garcia-Sanz N., Fernandez-Carvajal A., Morenilla-Palao C.,
RA   Planells-Cases R., Fajardo-Sanchez E., Fernandez-Ballester G.,
RA   Ferrer-Montiel A.;
RT   "Identification of a tetramerization domain in the C-terminus of the
RT   vanilloid receptor.";
RL   J. Neurosci. 24:5307-5314(2004).
RN   [22]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=15857679; DOI=10.1016/j.molbrainres.2004.12.003;
RA   Toth A., Boczan J., Kedei N., Lizanecz E., Bagi Z., Papp Z., Edes I.,
RA   Csiba L., Blumberg P.M.;
RT   "Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult
RT   rat brain.";
RL   Brain Res. Mol. Brain Res. 135:162-168(2005).
RN   [23]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=20510930; DOI=10.1016/j.cell.2010.03.052;
RA   Bohlen C.J., Priel A., Zhou S., King D., Siemens J., Julius D.;
RT   "A bivalent tarantula toxin activates the capsaicin receptor, TRPV1, by
RT   targeting the outer pore domain.";
RL   Cell 141:834-845(2010).
RN   [24]
RP   FUNCTION.
RX   PubMed=21076423; DOI=10.1038/nn.2684;
RA   Chavez A.E., Chiu C.Q., Castillo P.E.;
RT   "TRPV1 activation by endogenous anandamide triggers postsynaptic long-term
RT   depression in dentate gyrus.";
RL   Nat. Neurosci. 13:1511-1518(2010).
RN   [25] {ECO:0007744|PDB:2NYJ, ECO:0007744|PDB:2PNN}
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 101-364 IN COMPLEX WITH ATP,
RP   FUNCTION, ACTIVITY REGULATION, SUBCELLULAR LOCATION, ATP-BINDING,
RP   CALMODULIN-BINDING, MUTAGENESIS OF LYS-155; LYS-160; TYR-199 AND GLN-202,
RP   AND ANKYRIN REPEATS.
RX   PubMed=17582331; DOI=10.1016/j.neuron.2007.05.027;
RA   Lishko P.V., Procko E., Jin X., Phelps C.B., Gaudet R.;
RT   "The ankyrin repeats of TRPV1 bind multiple ligands and modulate channel
RT   sensitivity.";
RL   Neuron 54:905-918(2007).
RN   [26] {ECO:0007744|PDB:3SUI}
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 767-801 IN COMPLEX WITH CALM,
RP   FUNCTION, MUTAGENESIS OF LYS-155; ARG-785; TRP-787 AND LYS-788,
RP   CALMODULIN-BINDING, INTERACTION WITH CALM, AND ACTIVITY REGULATION.
RX   PubMed=23109716; DOI=10.1085/jgp.201210810;
RA   Lau S.Y., Procko E., Gaudet R.;
RT   "Distinct properties of Ca2+-calmodulin binding to N- and C-terminal
RT   regulatory regions of the TRPV1 channel.";
RL   J. Gen. Physiol. 140:541-555(2012).
RN   [27] {ECO:0007744|PDB:3J5P}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.27 ANGSTROMS), FUNCTION, SUBCELLULAR
RP   LOCATION, TOPOLOGY, ANK REPEATS, AND SUBUNIT.
RX   PubMed=24305160; DOI=10.1038/nature12822;
RA   Liao M., Cao E., Julius D., Cheng Y.;
RT   "Structure of the TRPV1 ion channel determined by electron cryo-
RT   microscopy.";
RL   Nature 504:107-112(2013).
RN   [28] {ECO:0007744|PDB:3J5Q, ECO:0007744|PDB:3J5R}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.8 ANGSTROMS) IN COMPLEXES WITH
RP   CAPSAICIN AND TARANTULA DOUBLE-KNOT TOXIN, AND SUBUNIT.
RX   PubMed=24305161; DOI=10.1038/nature12823;
RA   Cao E., Liao M., Cheng Y., Julius D.;
RT   "TRPV1 structures in distinct conformations reveal activation mechanisms.";
RL   Nature 504:113-118(2013).
RN   [29] {ECO:0007744|PDB:5IRX, ECO:0007744|PDB:5IRZ, ECO:0007744|PDB:5IS0}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.95 ANGSTROMS) OF 110-764 OF APOPROTEIN
RP   AND IN COMPLEX WITH AGONIST, SUBUNIT, TOPOLOGY, AND LIPID-BINDING.
RX   PubMed=27281200; DOI=10.1038/nature17964;
RA   Gao Y., Cao E., Julius D., Cheng Y.;
RT   "TRPV1 structures in nanodiscs reveal mechanisms of ligand and lipid
RT   action.";
RL   Nature 534:347-351(2016).
CC   -!- FUNCTION: Ligand-activated non-selective calcium permeant cation
CC       channel involved in detection of noxious chemical and thermal stimuli.
CC       Seems to mediate proton influx and may be involved in intracellular
CC       acidosis in nociceptive neurons. Involved in mediation of inflammatory
CC       pain and hyperalgesia. Sensitized by a phosphatidylinositol second
CC       messenger system activated by receptor tyrosine kinases, which involves
CC       PKC isozymes and PCL. Activation by vanilloids, like capsaicin, and
CC       temperatures higher than 42 degrees Celsius, exhibits a time- and
CC       Ca(2+)-dependent outward rectification, followed by a long-lasting
CC       refractory state. Mild extracellular acidic pH (6.5) potentiates
CC       channel activation by noxious heat and vanilloids, whereas acidic
CC       conditions (pH <6) directly activate the channel. Can be activated by
CC       endogenous compounds, including 12-hydroperoxytetraenoic acid and
CC       bradykinin. Acts as ionotropic endocannabinoid receptor with central
CC       neuromodulatory effects. Triggers a form of long-term depression
CC       (TRPV1-LTD) mediated by the endocannabinoid anandamine in the
CC       hippocampus and nucleus accumbens by affecting AMPA receptors
CC       endocytosis. {ECO:0000269|PubMed:11140687, ECO:0000269|PubMed:11418861,
CC       ECO:0000269|PubMed:11578842, ECO:0000269|PubMed:12095983,
CC       ECO:0000269|PubMed:12194871, ECO:0000269|PubMed:12764195,
CC       ECO:0000269|PubMed:12808128, ECO:0000269|PubMed:14523239,
CC       ECO:0000269|PubMed:14630912, ECO:0000269|PubMed:15173182,
CC       ECO:0000269|PubMed:17582331, ECO:0000269|PubMed:20510930,
CC       ECO:0000269|PubMed:21076423, ECO:0000269|PubMed:23109716,
CC       ECO:0000269|PubMed:24305160, ECO:0000269|PubMed:9349813}.
CC   -!- FUNCTION: [Isoform 3]: Does not display channel activity in response to
CC       noxious chemical compounds, such as capsaicin and the vanilloid
CC       resiniferatoxin. Channel activity is not elicited by mildly acidic
CC       extracellular pH, and only slight channel activity is observed in
CC       response to noxiuos heat stimuli. {ECO:0000269|PubMed:10644739}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671,
CC         ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:11140687,
CC         ECO:0000269|PubMed:12095983, ECO:0000269|PubMed:12194871,
CC         ECO:0000269|PubMed:14523239, ECO:0000269|PubMed:9349813};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Mg(2+)(in) = Mg(2+)(out); Xref=Rhea:RHEA:29827,
CC         ChEBI:CHEBI:18420; Evidence={ECO:0000269|PubMed:9349813};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Na(+)(in) = Na(+)(out); Xref=Rhea:RHEA:34963,
CC         ChEBI:CHEBI:29101; Evidence={ECO:0000269|PubMed:9349813};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=K(+)(in) = K(+)(out); Xref=Rhea:RHEA:29463, ChEBI:CHEBI:29103;
CC         Evidence={ECO:0000269|PubMed:9349813};
CC   -!- ACTIVITY REGULATION: Channel activity is activated via the interaction
CC       with PIRT and phosphatidylinositol 4,5-bisphosphate (PIP2). Both PIRT
CC       and PIP2 are required to activate channel activity (By similarity). The
CC       channel is sensitized by ATP binding. Repeated stimulation with
CC       capsaicin gives rise to progressively smaller responses, due to
CC       desensitization. This desensitization is triggered by the influx of
CC       calcium ions and is inhibited by elevated ATP levels. Ca(2+) and CALM
CC       displace ATP from its binding site and trigger a conformation change
CC       that leads to a closed, desensitized channel. Intracellular PIP2
CC       inhibits desensitization. The double-knot toxin (DkTx) from the Chinese
CC       earth tiger tarantula activates the channel and traps it in an open
CC       conformation. The Scolopendra mutilans RhTx toxin potentiates the heat
CC       activation pathway mediated by this channel by binding to the charge-
CC       rich outer pore region (in an activated state) (By similarity).
CC       {ECO:0000250|UniProtKB:Q704Y3, ECO:0000269|PubMed:17582331,
CC       ECO:0000269|PubMed:20510930, ECO:0000269|PubMed:23109716}.
CC   -!- SUBUNIT: Interacts with PIRT (By similarity). Homotetramer
CC       (PubMed:15190102, PubMed:24305160, PubMed:24305161, PubMed:27281200).
CC       May also form a heteromeric channel with TRPV3 (By similarity).
CC       Interacts with CALM, PRKCM and CSK (PubMed:12808128, PubMed:15084474,
CC       PubMed:15471852, PubMed:17582331). Interacts with PRKCG and NTRK1,
CC       probably by forming a trimeric complex (PubMed:11418861). Interacts
CC       with the Scolopendra mutilans RhTx toxin (By similarity). Interacts
CC       with the spider Tau-theraphotoxin-Hs1a (PubMed:27281200). Interacts
CC       with TMEM100 (By similarity). Interacts with PACS2 (By similarity).
CC       {ECO:0000250|UniProtKB:Q704Y3, ECO:0000250|UniProtKB:Q8NER1,
CC       ECO:0000269|PubMed:11418861, ECO:0000269|PubMed:12808128,
CC       ECO:0000269|PubMed:15084474, ECO:0000269|PubMed:15190102,
CC       ECO:0000269|PubMed:15471852, ECO:0000269|PubMed:23109716,
CC       ECO:0000269|PubMed:24305160, ECO:0000269|PubMed:24305161,
CC       ECO:0000269|PubMed:27281200}.
CC   -!- INTERACTION:
CC       O35433; O35433: Trpv1; NbExp=11; IntAct=EBI-2794004, EBI-2794004;
CC       O35433; P0CH43; Xeno; NbExp=2; IntAct=EBI-2794004, EBI-2793994;
CC       O35433-1; O35433-1: Trpv1; NbExp=3; IntAct=EBI-15703031, EBI-15703031;
CC   -!- SUBCELLULAR LOCATION: Postsynaptic cell membrane
CC       {ECO:0000269|PubMed:15857679}; Multi-pass membrane protein
CC       {ECO:0000305}. Cell projection, dendritic spine membrane
CC       {ECO:0000269|PubMed:15857679}; Multi-pass membrane protein
CC       {ECO:0000305}. Cell membrane {ECO:0000269|PubMed:11578842,
CC       ECO:0000269|PubMed:15857679, ECO:0000269|PubMed:9349813}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:24305160,
CC       ECO:0000269|PubMed:24305161, ECO:0000269|PubMed:27281200}. Note=Mostly,
CC       but not exclusively expressed in postsynaptic dendritic spines.
CC       {ECO:0000269|PubMed:15857679}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=VR1L1;
CC         IsoId=O35433-1; Sequence=Displayed;
CC       Name=2; Synonyms=VR1L2;
CC         IsoId=O35433-2; Sequence=VSP_013432;
CC       Name=3; Synonyms=VR.5'sv;
CC         IsoId=O35433-3; Sequence=VSP_013431, VSP_013432;
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in trigeminal and dorsal
CC       root sensory ganglia. Expressed also in hippocampus, cortex,
CC       cerebellum, olfactory bulb, mesencephalon and hindbrain. High
CC       expression in the cell bodies and dendrites of neurons in the
CC       hippocampus and in the cortex. In the brain detected also in astrocytes
CC       and pericytes (at protein level) (PubMed:15857679). Isoform 1 and
CC       isoform 3 are expressed in brain and peripheral blood mononuclear
CC       cells. {ECO:0000269|PubMed:10644739, ECO:0000269|PubMed:15857679,
CC       ECO:0000269|PubMed:9349813}.
CC   -!- DOMAIN: The association domain (AD) is necessary for self-association.
CC       {ECO:0000269|PubMed:15190102}.
CC   -!- PTM: Phosphorylation by PKA reverses capsaicin-induced
CC       dephosphorylation at multiple sites, probably including Ser-116 as a
CC       major phosphorylation site. Phosphorylation by CAMKII seems to regulate
CC       binding to vanilloids. Phosphorylated and modulated by PRKCE, PRKCM and
CC       probably PRKCZ. Dephosphorylation by calcineurin seems to lead to
CC       receptor desensitization and phosphorylation by CAMKII recovers
CC       activity. {ECO:0000269|PubMed:11884385, ECO:0000269|PubMed:12194871,
CC       ECO:0000269|PubMed:14630912, ECO:0000269|PubMed:15471852}.
CC   -!- MISCELLANEOUS: Responses evoked by capsaicin, but not by low pH and
CC       heat, can be antagonized by capsazepine.
CC   -!- MISCELLANEOUS: [Isoform 3]: Inactive. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the transient receptor (TC 1.A.4) family. TrpV
CC       subfamily. TRPV1 sub-subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF029310; AAC53398.1; -; mRNA.
DR   EMBL; AF158248; AAF28389.1; -; mRNA.
DR   EMBL; AB041029; BAA94306.1; -; mRNA.
DR   EMBL; AB040873; BAA94307.1; -; mRNA.
DR   EMBL; AF327067; AAK83151.1; -; Genomic_DNA.
DR   EMBL; AF327067; AAK83152.1; -; Genomic_DNA.
DR   PIR; T09054; T09054.
DR   RefSeq; NP_114188.1; NM_031982.1. [O35433-1]
DR   PDB; 2NYJ; X-ray; 3.20 A; A=101-364.
DR   PDB; 2PNN; X-ray; 2.70 A; A=101-364.
DR   PDB; 3J5P; EM; 3.28 A; A/B/C/D=111-719.
DR   PDB; 3J5Q; EM; 3.80 A; B/D/E/G=111-719.
DR   PDB; 3J5R; EM; 4.20 A; A/B/C/D=111-719.
DR   PDB; 3J9J; EM; -; A/B/C/D=111-719.
DR   PDB; 3SUI; X-ray; 1.95 A; B=767-801.
DR   PDB; 5IRX; EM; 2.95 A; A/B/C/D=110-764.
DR   PDB; 5IRZ; EM; 3.28 A; B/C/D/E=110-764.
DR   PDB; 5IS0; EM; 3.43 A; B/C/D/E=110-764.
DR   PDB; 7L2H; EM; 2.63 A; A/B/C/D=2-838.
DR   PDB; 7L2I; EM; 3.70 A; A/B/C/D=2-838.
DR   PDB; 7L2J; EM; 3.66 A; A/B/C/D=2-838.
DR   PDB; 7L2K; EM; 3.89 A; A/B/C/D=2-838.
DR   PDB; 7L2L; EM; 3.42 A; A/B/C/D=2-838.
DR   PDB; 7L2M; EM; 3.84 A; A/B/C/D=2-838.
DR   PDB; 7L2N; EM; 3.09 A; A/B/C/D=2-838.
DR   PDB; 7L2O; EM; 3.64 A; A/B/C/D=2-838.
DR   PDB; 7L2P; EM; 2.60 A; A/B/C/D=110-764.
DR   PDB; 7L2R; EM; 3.30 A; A/B/C/D=110-764.
DR   PDB; 7L2S; EM; 2.71 A; A/B/C/D=110-764.
DR   PDB; 7L2T; EM; 3.08 A; A/B/C/D=110-764.
DR   PDB; 7L2U; EM; 3.47 A; A/B/C/D=110-764.
DR   PDB; 7L2V; EM; 3.64 A; A/B/C/D=110-764.
DR   PDB; 7L2W; EM; 3.16 A; A/B/C/D=110-764.
DR   PDB; 7L2X; EM; 3.26 A; A/B/C/D=110-764.
DR   PDB; 7LP9; EM; 2.63 A; A/B/C/D=1-838.
DR   PDB; 7LPA; EM; 3.37 A; A/B/C/D=1-838.
DR   PDB; 7LPB; EM; 3.54 A; A/B/C/D=1-838.
DR   PDB; 7LPC; EM; 3.06 A; A/B/C/D=1-838.
DR   PDB; 7LPD; EM; 3.55 A; A/B/C/D=1-838.
DR   PDB; 7LPE; EM; 3.72 A; A/B/C/D=1-838.
DR   PDB; 7MZ5; EM; 2.76 A; A/B/C/D=2-838.
DR   PDB; 7MZ6; EM; 2.91 A; A/B/C/D=110-764.
DR   PDB; 7MZ7; EM; 3.35 A; A/B/C/D=110-764.
DR   PDB; 7MZ9; EM; 3.18 A; A/B/C/D=110-764.
DR   PDB; 7MZA; EM; 3.46 A; A/B/C/D=110-764.
DR   PDB; 7MZB; EM; 3.72 A; A/B/C/D=110-764.
DR   PDB; 7MZC; EM; 3.03 A; A/B/C/D=110-764.
DR   PDB; 7MZD; EM; 2.90 A; A/B/C/D=110-764.
DR   PDB; 7MZE; EM; 3.42 A; A/B/C/D=110-764.
DR   PDB; 7RQU; EM; 3.05 A; A/B/C/D=1-838.
DR   PDB; 7RQV; EM; 3.45 A; A/B/C/D=1-838.
DR   PDB; 7RQW; EM; 3.11 A; A/B/C/D=1-838.
DR   PDB; 7RQX; EM; 3.36 A; A/B/C/D=1-838.
DR   PDB; 7RQY; EM; 3.04 A; A/B/C/D=1-838.
DR   PDB; 7RQZ; EM; 3.32 A; A/B/C/D=1-838.
DR   PDB; 8T0C; EM; 3.50 A; A/B/C/D=1-838.
DR   PDB; 8T0E; EM; 3.30 A; A/B/C/D=1-838.
DR   PDB; 8T0Y; EM; 3.50 A; A/B/C/D=1-838.
DR   PDB; 8T10; EM; 3.70 A; A/B/C/D=1-838.
DR   PDB; 8T3L; EM; 3.60 A; A/B/C/D=110-764.
DR   PDB; 8T3M; EM; 3.50 A; A/B/C/D=110-764.
DR   PDB; 8U2Z; EM; 3.60 A; A/B/C/D=110-764.
DR   PDB; 8U30; EM; 3.00 A; A/B/C/D=1-838.
DR   PDB; 8U3A; EM; 2.30 A; A/D=110-764.
DR   PDB; 8U3C; EM; 2.30 A; A/D=1-838.
DR   PDB; 8U3J; EM; 2.90 A; A/B/C/D=197-753.
DR   PDB; 8U3L; EM; 3.70 A; A/B/C/D=1-838.
DR   PDB; 8U43; EM; 2.40 A; A/B/C/D=110-764.
DR   PDB; 8U4D; EM; 2.20 A; A/B/C/D=110-764.
DR   PDBsum; 2NYJ; -.
DR   PDBsum; 2PNN; -.
DR   PDBsum; 3J5P; -.
DR   PDBsum; 3J5Q; -.
DR   PDBsum; 3J5R; -.
DR   PDBsum; 3J9J; -.
DR   PDBsum; 3SUI; -.
DR   PDBsum; 5IRX; -.
DR   PDBsum; 5IRZ; -.
DR   PDBsum; 5IS0; -.
DR   PDBsum; 7L2H; -.
DR   PDBsum; 7L2I; -.
DR   PDBsum; 7L2J; -.
DR   PDBsum; 7L2K; -.
DR   PDBsum; 7L2L; -.
DR   PDBsum; 7L2M; -.
DR   PDBsum; 7L2N; -.
DR   PDBsum; 7L2O; -.
DR   PDBsum; 7L2P; -.
DR   PDBsum; 7L2R; -.
DR   PDBsum; 7L2S; -.
DR   PDBsum; 7L2T; -.
DR   PDBsum; 7L2U; -.
DR   PDBsum; 7L2V; -.
DR   PDBsum; 7L2W; -.
DR   PDBsum; 7L2X; -.
DR   PDBsum; 7LP9; -.
DR   PDBsum; 7LPA; -.
DR   PDBsum; 7LPB; -.
DR   PDBsum; 7LPC; -.
DR   PDBsum; 7LPD; -.
DR   PDBsum; 7LPE; -.
DR   PDBsum; 7MZ5; -.
DR   PDBsum; 7MZ6; -.
DR   PDBsum; 7MZ7; -.
DR   PDBsum; 7MZ9; -.
DR   PDBsum; 7MZA; -.
DR   PDBsum; 7MZB; -.
DR   PDBsum; 7MZC; -.
DR   PDBsum; 7MZD; -.
DR   PDBsum; 7MZE; -.
DR   PDBsum; 7RQU; -.
DR   PDBsum; 7RQV; -.
DR   PDBsum; 7RQW; -.
DR   PDBsum; 7RQX; -.
DR   PDBsum; 7RQY; -.
DR   PDBsum; 7RQZ; -.
DR   PDBsum; 8T0C; -.
DR   PDBsum; 8T0E; -.
DR   PDBsum; 8T0Y; -.
DR   PDBsum; 8T10; -.
DR   PDBsum; 8T3L; -.
DR   PDBsum; 8T3M; -.
DR   PDBsum; 8U2Z; -.
DR   PDBsum; 8U30; -.
DR   PDBsum; 8U3A; -.
DR   PDBsum; 8U3C; -.
DR   PDBsum; 8U3J; -.
DR   PDBsum; 8U3L; -.
DR   PDBsum; 8U43; -.
DR   PDBsum; 8U4D; -.
DR   AlphaFoldDB; O35433; -.
DR   EMDB; EMD-23128; -.
DR   EMDB; EMD-23129; -.
DR   EMDB; EMD-23130; -.
DR   EMDB; EMD-23131; -.
DR   EMDB; EMD-23132; -.
DR   EMDB; EMD-23133; -.
DR   EMDB; EMD-23134; -.
DR   EMDB; EMD-23135; -.
DR   EMDB; EMD-23136; -.
DR   EMDB; EMD-23138; -.
DR   EMDB; EMD-23139; -.
DR   EMDB; EMD-23140; -.
DR   EMDB; EMD-23141; -.
DR   EMDB; EMD-23142; -.
DR   EMDB; EMD-23143; -.
DR   EMDB; EMD-23144; -.
DR   EMDB; EMD-23161; -.
DR   EMDB; EMD-23473; -.
DR   EMDB; EMD-23474; -.
DR   EMDB; EMD-23475; -.
DR   EMDB; EMD-23476; -.
DR   EMDB; EMD-23478; -.
DR   EMDB; EMD-23479; -.
DR   EMDB; EMD-24083; -.
DR   EMDB; EMD-24084; -.
DR   EMDB; EMD-24085; -.
DR   EMDB; EMD-24086; -.
DR   EMDB; EMD-24087; -.
DR   EMDB; EMD-24088; -.
DR   EMDB; EMD-24089; -.
DR   EMDB; EMD-24090; -.
DR   EMDB; EMD-24091; -.
DR   EMDB; EMD-24636; -.
DR   EMDB; EMD-24637; -.
DR   EMDB; EMD-24638; -.
DR   EMDB; EMD-24639; -.
DR   EMDB; EMD-24640; -.
DR   EMDB; EMD-24641; -.
DR   EMDB; EMD-40940; -.
DR   EMDB; EMD-40941; -.
DR   EMDB; EMD-40949; -.
DR   EMDB; EMD-40951; -.
DR   EMDB; EMD-41005; -.
DR   EMDB; EMD-41006; -.
DR   EMDB; EMD-41847; -.
DR   EMDB; EMD-41848; -.
DR   EMDB; EMD-41855; -.
DR   EMDB; EMD-41857; -.
DR   EMDB; EMD-41864; -.
DR   EMDB; EMD-41866; -.
DR   EMDB; EMD-41873; -.
DR   EMDB; EMD-41879; -.
DR   EMDB; EMD-5776; -.
DR   EMDB; EMD-5777; -.
DR   EMDB; EMD-5778; -.
DR   EMDB; EMD-8117; -.
DR   EMDB; EMD-8118; -.
DR   EMDB; EMD-8119; -.
DR   EMDB; EMD-8120; -.
DR   SMR; O35433; -.
DR   BioGRID; 249845; 5.
DR   DIP; DIP-56949N; -.
DR   IntAct; O35433; 3.
DR   MINT; O35433; -.
DR   STRING; 10116.ENSRNOP00000026493; -.
DR   BindingDB; O35433; -.
DR   ChEMBL; CHEMBL5102; -.
DR   DrugCentral; O35433; -.
DR   GuidetoPHARMACOLOGY; 507; -.
DR   TCDB; 1.A.4.2.1; the transient receptor potential ca2+/cation channel (trp-cc) family.
DR   GlyCosmos; O35433; 1 site, No reported glycans.
DR   GlyGen; O35433; 1 site.
DR   iPTMnet; O35433; -.
DR   PhosphoSitePlus; O35433; -.
DR   PaxDb; 10116-ENSRNOP00000026493; -.
DR   ABCD; O35433; 2 sequenced antibodies.
DR   Ensembl; ENSRNOT00000026493.7; ENSRNOP00000026493.3; ENSRNOG00000019486.9. [O35433-1]
DR   Ensembl; ENSRNOT00000093394.2; ENSRNOP00000086172.1; ENSRNOG00000019486.9. [O35433-2]
DR   GeneID; 83810; -.
DR   KEGG; rno:83810; -.
DR   AGR; RGD:628841; -.
DR   CTD; 7442; -.
DR   RGD; 628841; Trpv1.
DR   eggNOG; KOG3676; Eukaryota.
DR   GeneTree; ENSGT00940000160870; -.
DR   HOGENOM; CLU_012795_1_0_1; -.
DR   InParanoid; O35433; -.
DR   OMA; YQYLHQN; -.
DR   OrthoDB; 1003028at2759; -.
DR   PhylomeDB; O35433; -.
DR   TreeFam; TF314711; -.
DR   Reactome; R-RNO-3295583; TRP channels.
DR   EvolutionaryTrace; O35433; -.
DR   PRO; PR:O35433; -.
DR   Proteomes; UP000002494; Chromosome 10.
DR   Bgee; ENSRNOG00000019486; Expressed in adult mammalian kidney and 16 other cell types or tissues.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0032591; C:dendritic spine membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0098982; C:GABA-ergic synapse; ISO:RGD.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; ISO:RGD.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045211; C:postsynaptic membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0005262; F:calcium channel activity; IDA:UniProtKB.
DR   GO; GO:0005516; F:calmodulin binding; IDA:UniProtKB.
DR   GO; GO:0017081; F:chloride channel regulator activity; IDA:RGD.
DR   GO; GO:0005231; F:excitatory extracellular ligand-gated monoatomic ion channel activity; IDA:UniProtKB.
DR   GO; GO:0005230; F:extracellular ligand-gated monoatomic ion channel activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0015278; F:intracellularly gated calcium channel activity; IMP:UniProtKB.
DR   GO; GO:0015276; F:ligand-gated monoatomic ion channel activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005261; F:monoatomic cation channel activity; IDA:RGD.
DR   GO; GO:0008324; F:monoatomic cation transmembrane transporter activity; IDA:MGI.
DR   GO; GO:0035091; F:phosphatidylinositol binding; IDA:UniProtKB.
DR   GO; GO:0051219; F:phosphoprotein binding; ISO:RGD.
DR   GO; GO:0097603; F:temperature-gated ion channel activity; ISO:RGD.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IDA:UniProtKB.
DR   GO; GO:0048266; P:behavioral response to pain; ISO:RGD.
DR   GO; GO:0098703; P:calcium ion import across plasma membrane; IDA:UniProtKB.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0006816; P:calcium ion transport; IDA:UniProtKB.
DR   GO; GO:0071468; P:cellular response to acidic pH; IDA:UniProtKB.
DR   GO; GO:0071312; P:cellular response to alkaloid; IMP:UniProtKB.
DR   GO; GO:0071318; P:cellular response to ATP; IDA:UniProtKB.
DR   GO; GO:0071345; P:cellular response to cytokine stimulus; IDA:UniProtKB.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEP:RGD.
DR   GO; GO:0034605; P:cellular response to heat; IDA:UniProtKB.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IEP:RGD.
DR   GO; GO:0071502; P:cellular response to temperature stimulus; IEP:RGD.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEP:RGD.
DR   GO; GO:0050968; P:detection of chemical stimulus involved in sensory perception of pain; ISO:RGD.
DR   GO; GO:0050965; P:detection of temperature stimulus involved in sensory perception of pain; ISO:RGD.
DR   GO; GO:0050960; P:detection of temperature stimulus involved in thermoception; ISO:RGD.
DR   GO; GO:0002024; P:diet induced thermogenesis; ISO:RGD.
DR   GO; GO:0001660; P:fever generation; ISO:RGD.
DR   GO; GO:0014047; P:glutamate secretion; IDA:RGD.
DR   GO; GO:0006629; P:lipid metabolic process; ISO:RGD.
DR   GO; GO:0001774; P:microglial cell activation; IMP:RGD.
DR   GO; GO:0034220; P:monoatomic ion transmembrane transport; ISO:RGD.
DR   GO; GO:0090212; P:negative regulation of establishment of blood-brain barrier; IMP:RGD.
DR   GO; GO:0010459; P:negative regulation of heart rate; IMP:RGD.
DR   GO; GO:0010917; P:negative regulation of mitochondrial membrane potential; IMP:RGD.
DR   GO; GO:0003085; P:negative regulation of systemic arterial blood pressure; IMP:RGD.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0002790; P:peptide secretion; ISO:RGD.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:RGD.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IDA:RGD.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:RGD.
DR   GO; GO:0051289; P:protein homotetramerization; IDA:UniProtKB.
DR   GO; GO:1901594; P:response to capsazepine; IMP:UniProtKB.
DR   GO; GO:0009408; P:response to heat; IDA:MGI.
DR   GO; GO:0048265; P:response to pain; ISO:RGD.
DR   GO; GO:0043434; P:response to peptide hormone; IEP:RGD.
DR   GO; GO:0009268; P:response to pH; IDA:MGI.
DR   GO; GO:0050954; P:sensory perception of mechanical stimulus; ISO:RGD.
DR   GO; GO:0019233; P:sensory perception of pain; ISO:RGD.
DR   GO; GO:0060083; P:smooth muscle contraction involved in micturition; ISO:RGD.
DR   GO; GO:0001659; P:temperature homeostasis; ISO:RGD.
DR   GO; GO:0050955; P:thermoception; ISO:RGD.
DR   GO; GO:0014832; P:urinary bladder smooth muscle contraction; ISO:RGD.
DR   CDD; cd22196; TRPV1; 1.
DR   Gene3D; 1.10.287.70; -; 1.
DR   Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR024862; TRPV.
DR   InterPro; IPR008347; TrpV1-4.
DR   NCBIfam; TIGR00870; trp; 1.
DR   PANTHER; PTHR10582:SF17; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY V MEMBER 1; 1.
DR   PANTHER; PTHR10582; TRANSIENT RECEPTOR POTENTIAL ION CHANNEL PROTEIN; 1.
DR   Pfam; PF00023; Ank; 1.
DR   Pfam; PF12796; Ank_2; 1.
DR   Pfam; PF00520; Ion_trans; 1.
DR   PRINTS; PR01768; TRPVRECEPTOR.
DR   SMART; SM00248; ANK; 4.
DR   SUPFAM; SSF48403; Ankyrin repeat; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ANK repeat; ATP-binding; Calcium;
KW   Calcium channel; Calcium transport; Calmodulin-binding; Cell membrane;
KW   Cell projection; Glycoprotein; Ion channel; Ion transport; Lipid-binding;
KW   Membrane; Metal-binding; Nucleotide-binding; Phosphoprotein;
KW   Postsynaptic cell membrane; Reference proteome; Repeat; Synapse;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..838
FT                   /note="Transient receptor potential cation channel
FT                   subfamily V member 1"
FT                   /id="PRO_0000215341"
FT   TOPO_DOM        1..432
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:24305160,
FT                   ECO:0000269|PubMed:27281200"
FT   TRANSMEM        433..453
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:24305160,
FT                   ECO:0000269|PubMed:27281200"
FT   TOPO_DOM        454..471
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:24305160,
FT                   ECO:0000269|PubMed:27281200"
FT   TRANSMEM        472..497
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:24305160,
FT                   ECO:0000269|PubMed:27281200"
FT   TOPO_DOM        498..510
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:24305160,
FT                   ECO:0000269|PubMed:27281200"
FT   TRANSMEM        511..531
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:24305160,
FT                   ECO:0000269|PubMed:27281200"
FT   TOPO_DOM        532..535
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:24305160,
FT                   ECO:0000269|PubMed:27281200"
FT   TRANSMEM        536..556
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:24305160,
FT                   ECO:0000269|PubMed:27281200"
FT   TOPO_DOM        557..571
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:24305160,
FT                   ECO:0000269|PubMed:27281200"
FT   TRANSMEM        572..599
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:24305160,
FT                   ECO:0000269|PubMed:27281200"
FT   TOPO_DOM        600..626
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:24305160,
FT                   ECO:0000269|PubMed:27281200"
FT   INTRAMEM        627..649
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000269|PubMed:24305160,
FT                   ECO:0000269|PubMed:27281200, ECO:0000305|PubMed:10931826"
FT   TRANSMEM        658..686
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:24305160,
FT                   ECO:0000269|PubMed:27281200"
FT   TOPO_DOM        687..838
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:24305160,
FT                   ECO:0000269|PubMed:27281200"
FT   REPEAT          110..152
FT                   /note="ANK 1"
FT   REPEAT          153..199
FT                   /note="ANK 2"
FT   REPEAT          200..246
FT                   /note="ANK 3"
FT   REPEAT          247..282
FT                   /note="ANK 4"
FT   REPEAT          283..331
FT                   /note="ANK 5"
FT   REPEAT          332..358
FT                   /note="ANK 6"
FT   REGION          1..63
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          86..109
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          684..712
FT                   /note="AD"
FT                   /evidence="ECO:0000269|PubMed:15190102"
FT   REGION          767..801
FT                   /note="Interaction with calmodulin"
FT                   /evidence="ECO:0000269|PubMed:23109716"
FT   REGION          777..792
FT                   /note="Required for PIP2-mediated channel inhibition"
FT                   /evidence="ECO:0000269|PubMed:12764195"
FT   MOTIF           643..646
FT                   /note="Selectivity filter"
FT                   /evidence="ECO:0000305|PubMed:10931826"
FT   COMPBIAS        86..104
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         115
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0007744|PDB:2PNN"
FT   BINDING         155
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0007744|PDB:2PNN"
FT   BINDING         160
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0007744|PDB:2NYJ, ECO:0007744|PDB:2PNN"
FT   BINDING         164
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0007744|PDB:2NYJ, ECO:0007744|PDB:2PNN"
FT   BINDING         199..202
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0007744|PDB:2NYJ, ECO:0007744|PDB:2PNN"
FT   BINDING         210..211
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0007744|PDB:2PNN"
FT   BINDING         511..512
FT                   /ligand="resiniferatoxin"
FT                   /ligand_id="ChEBI:CHEBI:8809"
FT                   /ligand_note="agonist"
FT                   /evidence="ECO:0000269|PubMed:27281200,
FT                   ECO:0007744|PDB:5IRX"
FT   BINDING         550
FT                   /ligand="resiniferatoxin"
FT                   /ligand_id="ChEBI:CHEBI:8809"
FT                   /ligand_note="agonist"
FT                   /evidence="ECO:0000269|PubMed:27281200,
FT                   ECO:0007744|PDB:5IRX"
FT   BINDING         557
FT                   /ligand="resiniferatoxin"
FT                   /ligand_id="ChEBI:CHEBI:8809"
FT                   /ligand_note="agonist"
FT                   /evidence="ECO:0000269|PubMed:27281200,
FT                   ECO:0007744|PDB:5IRX"
FT   BINDING         646
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_note="ligand shared between two neighboring
FT                   subunits"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R186"
FT   MOD_RES         116
FT                   /note="Phosphoserine; by PKA and PKD"
FT                   /evidence="ECO:0000269|PubMed:12194871,
FT                   ECO:0000269|PubMed:15471852"
FT   MOD_RES         144
FT                   /note="Phosphothreonine; by PKA; in vitro"
FT                   /evidence="ECO:0000269|PubMed:12194871"
FT   MOD_RES         370
FT                   /note="Phosphothreonine; by PKA; in vitro"
FT                   /evidence="ECO:0000269|PubMed:12194871"
FT   MOD_RES         502
FT                   /note="Phosphoserine; by PKC/PRKCE"
FT                   /evidence="ECO:0000269|PubMed:11884385,
FT                   ECO:0000269|PubMed:12194871, ECO:0000269|PubMed:14630912"
FT   MOD_RES         704
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:14630912"
FT   MOD_RES         774
FT                   /note="Phosphoserine; by PKA; in vitro"
FT                   /evidence="ECO:0000269|PubMed:12194871"
FT   MOD_RES         800
FT                   /note="Phosphoserine; by PKC/PRKCE and PKC/PRKCZ"
FT                   /evidence="ECO:0000269|PubMed:11884385"
FT   MOD_RES         820
FT                   /note="Phosphoserine; by PKA; in vitro"
FT                   /evidence="ECO:0000269|PubMed:12194871"
FT   CARBOHYD        604
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11683872"
FT   VAR_SEQ         1..307
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:10644739"
FT                   /id="VSP_013431"
FT   VAR_SEQ         348..407
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:10644739,
FT                   ECO:0000303|PubMed:11578842"
FT                   /id="VSP_013432"
FT   MUTAGEN         114
FT                   /note="R->E: Abolishes capsaicin-evoked current and binding
FT                   to resiniferatoxin."
FT                   /evidence="ECO:0000269|PubMed:12228246"
FT   MUTAGEN         114
FT                   /note="Missing: Abolishes sensitivity to acid."
FT                   /evidence="ECO:0000269|PubMed:12228246"
FT   MUTAGEN         115
FT                   /note="R->D: Abolishes capsaicin-evoked current and binding
FT                   to resiniferatoxin."
FT                   /evidence="ECO:0000269|PubMed:12228246"
FT   MUTAGEN         116
FT                   /note="S->A: Abolishes phosphorylation by PKCM and enhances
FT                   channel response to capsaicin by PKCM."
FT                   /evidence="ECO:0000269|PubMed:15471852"
FT   MUTAGEN         155
FT                   /note="K->A: Abolishes ATP binding. Abolishes CALM binding.
FT                   Impairs normal desensitization by repeated exposure to
FT                   capsaicin."
FT                   /evidence="ECO:0000269|PubMed:17582331,
FT                   ECO:0000269|PubMed:23109716"
FT   MUTAGEN         160
FT                   /note="K->A: Abolishes ATP binding. Abolishes CALM
FT                   binding."
FT                   /evidence="ECO:0000269|PubMed:17582331"
FT   MUTAGEN         199
FT                   /note="Y->A: Strongly reduces affinity for ATP; when
FT                   associated with A-202."
FT                   /evidence="ECO:0000269|PubMed:17582331"
FT   MUTAGEN         202
FT                   /note="Q->A: Strongly reduces affinity for ATP; when
FT                   associated with A-199."
FT                   /evidence="ECO:0000269|PubMed:17582331"
FT   MUTAGEN         502
FT                   /note="S->A: Largely reduces PMA enhancement of capsaicin-
FT                   evoked currents, but no effect on direct activation by PMA.
FT                   Loss of activation by capsaicin and loss of vanilloid
FT                   binding; when associated with I-704."
FT                   /evidence="ECO:0000269|PubMed:11884385,
FT                   ECO:0000269|PubMed:14523239, ECO:0000269|PubMed:14630912"
FT   MUTAGEN         511
FT                   /note="Y->A: Loss of sensitivity to capsaicin."
FT                   /evidence="ECO:0000269|PubMed:14996838"
FT   MUTAGEN         547
FT                   /note="M->L: Reduces binding to resiniferatoxin."
FT                   /evidence="ECO:0000269|PubMed:14996838"
FT   MUTAGEN         550
FT                   /note="T->I: Reduces sensitivity to capsaicin 10-fold; no
FT                   effect on sensitivity to resiniferatoxin. Reduces binding
FT                   to resiniferatoxin."
FT                   /evidence="ECO:0000269|PubMed:14996838"
FT   MUTAGEN         636
FT                   /note="E->K: Abolishes channel activity. Restored channel
FT                   activity; when associated with E-639."
FT                   /evidence="ECO:0000269|PubMed:10931826"
FT   MUTAGEN         636
FT                   /note="E->Q: Slight modification of pore attributes."
FT                   /evidence="ECO:0000269|PubMed:10931826"
FT   MUTAGEN         639
FT                   /note="K->E: Restored channel activity; when associated
FT                   with K-636."
FT                   /evidence="ECO:0000269|PubMed:10931826"
FT   MUTAGEN         644
FT                   /note="M->Y: Slightly modifies channel permeability."
FT                   /evidence="ECO:0000269|PubMed:10931826"
FT   MUTAGEN         646
FT                   /note="D->N: Strongly reduces the affinity for pore blocker
FT                   ruthenium red and lowered channel permeability for Mg(2+)."
FT                   /evidence="ECO:0000269|PubMed:10931826"
FT   MUTAGEN         648
FT                   /note="E->Q: Minor modification of pore attributes."
FT                   /evidence="ECO:0000269|PubMed:10931826"
FT   MUTAGEN         651
FT                   /note="E->Q: Minor modification of pore attributes."
FT                   /evidence="ECO:0000269|PubMed:10931826"
FT   MUTAGEN         704
FT                   /note="T->A: No effect on PMA-induced enhancement of
FT                   capsaicin-evoked currents but reduces direct activation by
FT                   PMA."
FT                   /evidence="ECO:0000269|PubMed:14523239,
FT                   ECO:0000269|PubMed:14630912"
FT   MUTAGEN         704
FT                   /note="T->I: Loss of activation by capsaicin and loss of
FT                   vanilloid binding; when associated with A-502."
FT                   /evidence="ECO:0000269|PubMed:14523239,
FT                   ECO:0000269|PubMed:14630912"
FT   MUTAGEN         761
FT                   /note="E->K,Q: Abolishes capsaiin-evoked current and
FT                   binding to resiniferatoxin."
FT                   /evidence="ECO:0000269|PubMed:12228246"
FT   MUTAGEN         761
FT                   /note="Missing: Abolishes sensitivity to acid."
FT                   /evidence="ECO:0000269|PubMed:12228246"
FT   MUTAGEN         785
FT                   /note="R->Q: Strongly reduces CALM-binding and abolishes
FT                   PLC-mediated channel activity; when associated with Q-788."
FT                   /evidence="ECO:0000269|PubMed:12764195,
FT                   ECO:0000269|PubMed:23109716"
FT   MUTAGEN         787
FT                   /note="W->R: Reduces CALM-binding. Reduces desensitization
FT                   by repeated exposure to capsaicin."
FT                   /evidence="ECO:0000269|PubMed:23109716"
FT   MUTAGEN         788
FT                   /note="K->Q: Strongly reduces CALM-binding and abolishes
FT                   PLC-mediated channel activity; when associated with Q-785
FT                   or Q-797."
FT                   /evidence="ECO:0000269|PubMed:12764195,
FT                   ECO:0000269|PubMed:23109716"
FT   MUTAGEN         797
FT                   /note="R->Q: Abolishes PLC-mediated channel activity; when
FT                   associated with Q-788."
FT                   /evidence="ECO:0000269|PubMed:12764195"
FT   MUTAGEN         800
FT                   /note="S->A: Largely reduces direct activation of by PMA
FT                   and PMA-induced currents; no effect on receptor kinase-
FT                   induced currents."
FT                   /evidence="ECO:0000269|PubMed:11884385,
FT                   ECO:0000269|PubMed:12764195, ECO:0000269|PubMed:14523239"
FT   CONFLICT        18
FT                   /note="E -> D (in Ref. 3; BAA94307)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        36
FT                   /note="V -> A (in Ref. 4; AAK83151)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        48
FT                   /note="R -> G (in Ref. 3; BAA94306)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        51
FT                   /note="G -> W (in Ref. 3; BAA94306)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        96
FT                   /note="P -> Q (in Ref. 3; BAA94307)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        179
FT                   /note="V -> I (in Ref. 4; AAK83151)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        735
FT                   /note="K -> Q (in Ref. 3; BAA94306)"
FT                   /evidence="ECO:0000305"
FT   HELIX           114..123
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           127..129
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           132..139
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   TURN            146..148
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   TURN            151..153
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           157..162
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           172..183
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           187..190
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   STRAND          196..199
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           204..210
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           214..222
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   STRAND          227..229
FT                   /evidence="ECO:0007829|PDB:7RQY"
FT   HELIX           234..236
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   STRAND          240..242
FT                   /evidence="ECO:0007829|PDB:7LP9"
FT   HELIX           251..257
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           261..268
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   STRAND          271..273
FT                   /evidence="ECO:0007829|PDB:7RQY"
FT   STRAND          277..279
FT                   /evidence="ECO:0007829|PDB:7RQX"
FT   STRAND          282..284
FT                   /evidence="ECO:0007829|PDB:7RQZ"
FT   HELIX           287..294
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           299..319
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   STRAND          321..323
FT                   /evidence="ECO:0007829|PDB:7RQU"
FT   HELIX           325..327
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           336..343
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           346..353
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   TURN            356..358
FT                   /evidence="ECO:0007829|PDB:2NYJ"
FT   TURN            360..362
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           363..365
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   STRAND          367..373
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   STRAND          375..382
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   TURN            385..387
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   TURN            388..390
FT                   /evidence="ECO:0007829|PDB:5IS0"
FT   STRAND          391..393
FT                   /evidence="ECO:0007829|PDB:7LP9"
FT   HELIX           395..400
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   STRAND          406..408
FT                   /evidence="ECO:0007829|PDB:7MZ5"
FT   HELIX           409..412
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           416..453
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   STRAND          459..462
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           469..499
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           501..504
FT                   /evidence="ECO:0007829|PDB:3J9J"
FT   HELIX           505..508
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           511..531
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           537..551
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           552..556
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           560..598
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   STRAND          601..603
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   STRAND          627..629
FT                   /evidence="ECO:0007829|PDB:5IRX"
FT   HELIX           630..638
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   TURN            639..643
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   STRAND          647..649
FT                   /evidence="ECO:0007829|PDB:5IS0"
FT   STRAND          652..654
FT                   /evidence="ECO:0007829|PDB:7L2L"
FT   HELIX           656..669
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   TURN            670..672
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           673..688
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           690..711
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   TURN            713..715
FT                   /evidence="ECO:0007829|PDB:7L2H"
FT   STRAND          717..720
FT                   /evidence="ECO:0007829|PDB:7LP9"
FT   STRAND          721..723
FT                   /evidence="ECO:0007829|PDB:7MZ5"
FT   STRAND          726..730
FT                   /evidence="ECO:0007829|PDB:7L2H"
FT   STRAND          732..734
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   STRAND          736..738
FT                   /evidence="ECO:0007829|PDB:7L2H"
FT   STRAND          739..741
FT                   /evidence="ECO:0007829|PDB:7RQZ"
FT   STRAND          742..747
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   STRAND          749..751
FT                   /evidence="ECO:0007829|PDB:7RQU"
FT   STRAND          758..760
FT                   /evidence="ECO:0007829|PDB:7L2P"
FT   HELIX           788..792
FT                   /evidence="ECO:0007829|PDB:3SUI"
FT   HELIX           793..795
FT                   /evidence="ECO:0007829|PDB:3SUI"
SQ   SEQUENCE   838 AA;  94948 MW;  DAFC80B12BDF71BF CRC64;
     MEQRASLDSE ESESPPQENS CLDPPDRDPN CKPPPVKPHI FTTRSRTRLF GKGDSEEASP
     LDCPYEEGGL ASCPIITVSS VLTIQRPGDG PASVRPSSQD SVSAGEKPPR LYDRRSIFDA
     VAQSNCQELE SLLPFLQRSK KRLTDSEFKD PETGKTCLLK AMLNLHNGQN DTIALLLDVA
     RKTDSLKQFV NASYTDSYYK GQTALHIAIE RRNMTLVTLL VENGADVQAA ANGDFFKKTK
     GRPGFYFGEL PLSLAACTNQ LAIVKFLLQN SWQPADISAR DSVGNTVLHA LVEVADNTVD
     NTKFVTSMYN EILILGAKLH PTLKLEEITN RKGLTPLALA ASSGKIGVLA YILQREIHEP
     ECRHLSRKFT EWAYGPVHSS LYDLSCIDTC EKNSVLEVIA YSSSETPNRH DMLLVEPLNR
     LLQDKWDRFV KRIFYFNFFV YCLYMIIFTA AAYYRPVEGL PPYKLKNTVG DYFRVTGEIL
     SVSGGVYFFF RGIQYFLQRR PSLKSLFVDS YSEILFFVQS LFMLVSVVLY FSQRKEYVAS
     MVFSLAMGWT NMLYYTRGFQ QMGIYAVMIE KMILRDLCRF MFVYLVFLFG FSTAVVTLIE
     DGKNNSLPME STPHKCRGSA CKPGNSYNSL YSTCLELFKF TIGMGDLEFT ENYDFKAVFI
     ILLLAYVILT YILLLNMLIA LMGETVNKIA QESKNIWKLQ RAITILDTEK SFLKCMRKAF
     RSGKLLQVGF TPDGKDDYRW CFRVDEVNWT TWNTNVGIIN EDPGNCEGVK RTLSFSLRSG
     RVSGRNWKNF ALVPLLRDAS TRDRHATQQE EVQLKHYTGS LKPEDAEVFK DSMVPGEK
//
